Verdinexor: A New Oral Treatment Option for Canine Lymphoma

1 hour CE

Watch On Demand

In this CE session, we’ll review the latest best practices for managing canine lymphoma. We’ll also talk about how the first FDA conditionally approved oral tablet for canine lymphoma, LAVERDIA™-CA1 (verdinexor), is giving veterinarians and dog owners more options and increasing access to cancer care.

Hosted by

Dr. David Bruyette


Chief Medical Officer


You'll learn:
  • Evolving protocols for canine lymphoma treatment
  • The role of primary care teams in treating lymphoma
  • How SINE drugs work and why they are different
  • When to consider LAVERDIA-CA1 for lymphoma patients
  • Guidelines to optimize patient outcomes

I acknowledge that by registering for this webinar Anivive may email me about this event and other events and news.

This program has been approved for 1.0 hour of continuing education credit in jurisdictions that recognize RACE approval. Anivive RACE Provider #50-30163